Navigation Links
FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
Date:11/8/2007

r ergot alkaloids [ergotamine, dihydroergotamine]) should be administered with caution in patients receiving SPRYCEL.

Long-term suppression of gastric acid secretion by use of H2 antagonists or proton pump inhibitors (e.g., famotidine and omeprazole) is likely to reduce dasatinib exposure. Therefore, concomitant use of H2 antagonists or proton pump inhibitors with SPRYCEL is not recommended. The use of antacids should be considered. Simultaneous administration of SPRYCEL and antacids should be avoided. If antacid therapy is needed, the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of SPRYCEL.

Pregnancy:

SPRYCEL may cause fetal harm when administered to a pregnant woman. Women should be advised of the potential hazard to the fetus and to avoid becoming pregnant.

Nursing Mothers:

It is unknown whether SPRYCEL is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue drug.

Adverse Reactions:

The safety data reflect exposure to SPRYCEL in 2,182 patients with leukemia in clinical studies (starting dosage 100 mg once daily, 140 mg once daily, 50 mg twice daily, or 70 mg twice daily). The majority of SPRYCEL- treated patients experienced adverse reactions at some time. Drug was discontinued for adverse reactions in 9% of patients in chronic phase, 10% in accelerated phase, 15% in myeloid blast phase CML, and 8% in lymphoid blast phase CML or Ph+ ALL.

The most frequently reported adverse reactions (reported in greater than or equal to 20% of patients) included fluid retention events (37%), diarrhea (31%), headache (24%), skin rash (22%), nausea (22%), hemorrhage (21%), fatigue (21%), and dyspnea (20%).

The most frequently reported serious adverse reactions included pleural effusion (9%), pyrexia (3%), pneumonia (3%), infection (2%), febrile neutropenia (4%), gast
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
2. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
3. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
4. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
7. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
8. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
9. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
10. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
11. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... The report "1,6-Hexanediol Market by Application and ... analyzes the global market on the basis of ... details such as the key drivers, current trends ... Browse 81 Market Data Tables and 29 Figures ... “1,6-Hexanediol Market by Application and by Geography - ...
(Date:10/18/2014)... (PRWEB) October 18, 2014 The Asia-Pacific ... concerned market in Asia-Pacific with analysis and forecast of ... and is expected to reach $51,362.6 million by 2018, ... , Browse through the TOC of the Asia-Pacific hardware ... in-depth analysis provided. This also provides a glimpse of ...
(Date:10/18/2014)... 18, 2014 The Asian Electronic Medical Record ... Asian with analysis and forecast of revenue. The electronic medical ... to $2,328.0 million by 2018, at a CAGR of 9.4% ... the Asian Electronic Medical Record (EMR) market, to get an ... glimpse of the segmentation of the market in the same ...
(Date:10/18/2014)... to a new market research report “Hydraulic Fracturing Market ... Forecasts up till 2017”, hydraulic fracturing market will grow ... expected to increase from $40 billion in 2012 to ... same period. North America is expected to lead the ... horse power supplied by the year 2011. , Make ...
Breaking Biology Technology:1,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 21,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 31,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 41,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 5The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 3The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 2The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 3The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 4The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 5Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 2Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 3Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 4
... (Nasdaq: AMLN ) issued the following statement ... Eastbourne Capital Management, L.L.C., made public earlier today:"After significant ... unable to achieve a settlement with Eastbourne and Carl ... shareholders. Of course, we continue to remain open to ...
... ATLANTA, May 20 Germany will present itself ... locations at this year,s BIO,International Convention. Under the ... will provide invaluable insight into the,latest research results ... The,German research landscape and the regulatory framework conditions ...
... N.C., May 20 Asymchem Laboratories, Inc., a leading ... Products to the pharmaceutical industry, with sites in ... the recent addition of Dr. Chris Huber as ... the table over 15 years experience in the ...
Cached Biology Technology:Amylin Responds to Eastbourne Letter 2Amylin Responds to Eastbourne Letter 3Amylin Responds to Eastbourne Letter 4BIO International Convention 2009: Research Location Germany Presents Potential in Regenerative Medicine 2Dr. Chris Huber Joins Asymchem Laboratories Inc. as Director of Chemical Development 2
(Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
(Date:10/16/2014)... efficiently, they are anything but sustainable: environmental damage ... is becoming increasingly evident. Despite their disadvantages, however, ... regarded as the sole possibility of achieving higher ... Bernhard Schmid, an ecology professor at the University ... agriculture and forestry. After all, a new study ...
(Date:10/15/2014)... risk from strains of influenza virus increases with the ... become complacent that the most substantial threats have been ... pandemics arise when a new virus strain – against ... spreads in the human population. There have been five ... of which – the 1918 Spanish Flu – cost ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... photovoltaic (PV) cells world-wide produced a peak amount of electricity ... located in Europe. Similarly to previous years, this shows the ... new solar systems were installed. By the end of 2009, ... installed) was 16 GW, which is about 70% of the ...
... A surface molecule on bacteria that instructs bone cells ... bone disease, says a scientist speaking at the Society for ... from bacteria could be a way of treating painful bone ... by Meticillin-resistant Staphylococcus aureus (MRSA). Bone disease, ...
... 1. A Low-carb Diet Based on Animal Protein May ... low-carbohydrate diet produces weight loss and improves some cardiovascular ... may depend on the type of protein and fat ... a low-carbohydrate diet for 26 and 20 years respectively. ...
Cached Biology News:Three-quarters of new solar systems worldwide were installed in the EU in 2009 2Three-quarters of new solar systems worldwide were installed in the EU in 2009 3Interrupting death messages to treat bone disease 2Embargoed news from Annals of Internal Medicine 2
... transient, cytoplasmic expression of an N-terminal FLAG® ... or selection marker from bicistronic mRNA. ... and MCS2 for transcription of a single ... is useful for protein-protein interaction studies, multi-subunit ...
...
Mouse monoclonal antibody raised against a partial recombinant SCARB2. NCBI Entrez Gene ID = SCARB2...
Alpha-2-antiplasmin precursor (Alpha-2-plasmin inhibitor) (Alpha-2-PI) (Alpha-2-AP). [Source:Uniprot/SWISSPROT;Acc:P08697] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: